ClinicalTrials.gg
RecruitingNCT07484217CLARITYUpdated Oct 13, 2026

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

A Phase 3 interventional study of Solriamfetol 150 MG and Placebo in Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, sponsored by Axsome Therapeutics, Inc.. Recruiting at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Planned enrollment
2nd of 10
508 · median 320
Started
2026
the only one that year
Phase 3
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 3, and was the 10th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

Read the detailed description

The study will consist of a screening period, an open label solriamfetol treatment period, a double-blind randomized withdrawal period, and a follow-up period. Eligible subjects will be treated with open-label solriamfetol and monitored for clinical response. Subjects achieving clinical response will be randomized into the double-blind randomized withdrawal period in a 1:1 ratio to either continued treatment with solriamfetol or to switch to placebo, for the remainder of the double-blind period or until they experience relapse of depressive symptoms.

03

Conditions studied

  • Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Keywords

  • Solriamfetol
  • Sunosi
  • Major Depressive Disorder with excessive daytime sleepiness
  • Major Depressive Disorder
  • MDD
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
  • Trace amine-associated receptor 1 (TAAR1) agonist
  • Excessive daytime sleepiness
  • EDS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meets the criteria for MDD without psychotic features, based on the SCID-5-CT
  • Excessive daytime sleepiness symptoms
  • Able to comply with study procedures
  • Male or female, aged 18 to 65 years inclusive

Exclusion criteria

Exclusion Criteria:

  • Any medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms
  • Unable to comply with study procedures
  • Medically inappropriate for study participation in the opinion of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
508 participants (estimated)

Study arms

  • Experimental
    Solriamfetol 150mg

    * In the open-label period; * In the randomized double-blind period (if applicable)

    Drug: Solriamfetol 150 MG

  • Placebo comparator
    Placebo

    • In the randomized double-blind period (if applicable)

    Drug: Placebo

Interventions

  • Solriamfetol tablets, taken once daily

  • DrugPlacebo

    Placebo tablets, taken once daily

06

What researchers measure

Primary outcomes

  1. Time from randomization to relapse of depressive symptoms

    Time frame: Up to 24 weeks.

07

Study locations

40 of 40 sites recruiting
  • Clinical Research Site
    Tucson, Arizona 85704, United States
    Recruiting
  • Clinical Research Site
    Bellflower, California 90706, United States
    Recruiting
  • Clinical Research Site
    Chino, California 91710, United States
    Recruiting
  • Clinical Research Site
    Glendale, California 91206, United States
    Recruiting
  • Clinical Research Site
    Imperial, California 92251, United States
    Recruiting
  • Clinical Research Site
    Los Angeles, California 90015, United States
    Recruiting
  • Clinical Research Site
    Oceanside, California 92056, United States
    Recruiting
  • Clinical Research Site
    Redlands, California 92374, United States
    Recruiting
  • Clinical Research Site
    San Diego, California 92123, United States
    Recruiting
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
    Recruiting
  • Clinical Research Site
    Walnut Creek, California 94596, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33122, United States
    Recruiting
  • Clinical Research Site
    Miami, Florida 33176, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia 30331, United States
    Recruiting
  • Clinical Research Site
    Norcross, Georgia 30092, United States
    Recruiting
  • Clinical Research Site
    Snellville, Georgia 30078, United States
    Recruiting
  • Clinical Research Site
    Chicago, Illinois 60634, United States
    Recruiting
  • Clinical Research Site
    Pikesville, Maryland 21208, United States
    Recruiting
  • Clinical Research Site
    Springfield, Massachusetts 01103, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada 89119, United States
    Recruiting
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
    Recruiting
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
    Recruiting
  • Clinical Research Site
    Brooklyn, New York 11235, United States
    Recruiting
  • Clinical Research Site
    New York, New York 10036, United States
    Recruiting
  • Clinical Research Site
    New York, New York 10128, United States
    Recruiting
  • Clinical Research Site
    Staten Island, New York 10314, United States
    Recruiting
  • Clinical Research Site
    The Bronx, New York 10464, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
    Recruiting
  • Clinical Research Site
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Clinical Research Site
    Edmond, Oklahoma 73013, United States
    Recruiting
  • Clinical Research Site
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • Clinical Research Site
    Portland, Oregon 97210, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Clinical Research Site
    Austin, Texas 78759, United States
    Recruiting
  • Clinical Research Site
    Bellaire, Texas 77401, United States
    Recruiting
  • Clinical Research Site
    Dallas, Texas 75243, United States
    Recruiting
  • Clinical Research Site
    Houston, Texas 77007, United States
    Recruiting
  • Clinical Research Site
    San Antonio, Texas 78240, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 34 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Feb 23, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07484217
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Feb 23, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Study Director
Contact
sol-mdd-302@axsome.com
2123325061

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion